AP - Shares of Orexigen Therapeutics Inc. surged Thursday after the drugmaker said it signed a $1 billion co-development agreement for its experimental obesity drug Contrave with Takeda Pharmaceuticals.
AP - Supporters of a voter initiative that could help bring cheaper prescription drugs to North Dakota are hoping a legal technicality won't keep them from getting the issue placed on the ballot.
Reuters - A former hedge fund manager has been accused by a U.S. regulator of illegal insider trading in MedImmune Inc securities prior to the acquisition of the pharmaceutical company by Britain's AstraZeneca Plc.
Reuters - The U.S. Department of Justice will continue to "aggressively pursue" pharmaceutical companies that illegally market drugs for uses that have not been approved by health regulators, a top agency official said on Wednesday.
AP - Pfizer Inc. said Wednesday it will buy privately held FoldRx Pharmaceuticals Incl. for an undisclosed amount, expanding its pipeline of potential products.
Reuters - Rival anti-clotting drugs from Bayer (BAYGn.DE) and Bristol-Myers Squibb both impressed in clinical trials, keeping them firmly in the race to displace the old, problematic heart drug warfarin.
AFP - The board of directors at US biotechnology firm Genzyme has unanimously rejected an 18.5-billion-dollar takeover offer from French pharmaceutical giant Sanofi-Aventis, Genzyme said Monday.
AFP - French pharmaceutical group Sanofi-Aventis unveiled Sunday an 18.5 billion dollar (14.5 billion euro) offer for US biotechnology firm Genzyme, hinting it may launch a hostile bid.
Reuters - Swiss drugmaker Roche Holding AG said on Sunday it would not make any decision on job cuts this week, after Swiss newspaper Sonntag reported it could be about to cut thousands of positions.
I guess he wanted to let me know not to give up on my health. ((sidenote: I am not getting paid to endorse this book. It's only the truth speaking.)) 4 out of 4 Angel Wings! Review courtesy of Lisa Owens of The Angel Directory ...
AFP - The board of directors at US biotechnology firm Genzyme has unanimously rejected an 18.5-billion-dollar takeover offer from French pharmaceutical giant Sanofi-Aventis, Genzyme said Monday.
AFP - French pharmaceutical group Sanofi-Aventis unveiled Sunday an 18.5 billion dollar (14.5 billion euro) offer for US biotechnology firm Genzyme, hinting it may launch a hostile bid.